Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Piper Sandler analyst David Westenberg maintains Exact Sciences (NASDAQ:EXAS) with a Overweight and raises the price target ...
Oncoguard® Liver blood test delivers seven times greater sensitivity for very early-stage hepatocellular carcinoma (HCC) versus...
Wells Fargo analyst Brandon Couillard maintains Exact Sciences (NASDAQ:EXAS) with a Overweight and raises the price target f...
TD Cowen analyst Dan Brennan maintains Exact Sciences (NASDAQ:EXAS) with a Buy and raises the price target from $74 to $90.
TD Cowen analyst Dan Brennan maintains Exact Sciences (NASDAQ:EXAS) with a Buy and raises the price target from $74 to $90.
Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, o...
Baird analyst Catherine Schulte maintains Exact Sciences (NASDAQ:EXAS) with a Outperform and raises the price target from $7...
Benchmark analyst Bruce D. Jackson maintains Exact Sciences (NASDAQ:EXAS) with a Buy and raises the price target from $60 to...
